BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of the second cohort of eight healthy participants in its Phase 1 clinical trial of its lead product candidate,

Kansas Health Information Network, Inc., DBA KONZA announced today it is one of the first organizations to have its application approved to continue to the testing and onboarding phase to become a Qualified Health Information Network (QHIN) under the Trusted Exchange Framework and Common Agreement (TEFCA) by the Office of the National Coordinator (ONC) for Health IT.

The International Space Station National Laboratory is soliciting flight projects for in-space production applications focused on advanced materials and manufacturing.

Pixium Vision SA announces that it has terminated its Convertible Note financing agreement with the European Select Growth Opportunities Fund, a US-based investor specializing in healthcare.

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of the first patient with Elucirem™ (gadopiclenol) injection following FDA approval in 2022.

Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel tumor necrosis factor superfamily receptor antagonist antibodies, announced updates on the company’s DOMab™ platform.

MDxHealth SA announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score test under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria.

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the research collaboration agreement established with GSK in 2020 has been amended to reflect that Vir will continue its ongoing efforts to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners.

Travere Therapeutics, Inc. announced that on February 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,700 shares of its common stock.